Trastuzumab Cardiac Toxicity: A Problem we Put our Heart Into
Abstract
Trastuzumab has gained a central role in the treatment of HER2-positive breast cancer, revolutionizing care in this setting. However, since the beginning of its use there have been concerns about its cardiac safety. Trastuzumab can give rise to cardiac toxicity, in some cases leading to discontinuation of treatment. Growing evidence shows that trastuzumab toxicity can be detected early or averted by means of new chemotherapy regimens using different anthracycline formulations or avoiding anthracyclines altogether. Moreover, patients in whom cardiac toxicity develops can be treated effectively and full cardiac function can be restored thanks to progress in drug management. Knowing the characteristics and proper management of trastuzumab toxicity is of paramount importance to grant patients in this setting the best available treatment.
Get full access to this article
View all access and purchase options for this article.
References
1. Slamon DJ Proto-oncogenes and human cancers. N Engl J Med 1987 317 15 955–957
2. Carter P Presta L Gorman CM et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992 89 10 4285–4289
3. Russell SD Blackwell KL Lawrence J et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010 28 21 3416–3421
4. Farolfi A Melegari E Aquilina M et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart 2013 99 9 634–639
5. Monsuez JJ Charniot JC Vignat N Artigou JY Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010 144 1 3–15
6. Vaz-Luis I Keating NL Lin NU Lii H Winer EP Freedman RA Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 2014 32 9 927–934
7. Serrano C Cortés J De Mattos-Arruda L et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012 23 4 897–902
8. Ozcelik C Erdmann B Pilz B et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 2002 99 13 8880–8885
9. Sandoo A Kitas GD Carmichael AR Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer. Anticancer Res 2014 34 3 1147–1151
10. Wadugu B Kühn B The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol 2012 302 11 H2139–H2147
11. Hao J Galindo CL Tran TL Sawyer DB Neuregulin-1β induces embryonic stem cell cardiomyogenesis via ErbB3/ErbB2 receptors. Biochem J 2014 458 2 335–341
12. Chaanine AH Hajjar RJ AKT signalling in the failing heart. Eur J Heart Fail 2011 13 8 825–829
13. Slamon D Eiermann W Robert N et al; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011 365 14 1273–1283
14. Baselga J Norton L Albanell J Kim YM Mendelsohn J Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998 58 13 2825–2831
15. Slamon DJ Leyland-Jones B Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 344 11 783–792
16. Gianni L Eiermann W Semiglazov V et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014 15 6 640–647
17. Buzdar AU Suman VJ Meric-Bernstam F et al; American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 2013 14 13 1317–1325
18. Morris PG Iyengar NM Patil S et al. Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer 2013 119 22 3943–3951
19. van Dalen EC van der Pal HJ Caron HN Kremer LC Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2009 4CD005008
20. Rayson D Suter TM Jackisch C et al. Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Ann Oncol 2012 23 7 1780–1788
21. Baselga J Manikhas A Cortés J et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol 2014 25 3 592–598
22. van Dalen EC Michiels EM Caron HN Kremer LC Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010 5CD005006
23. Joensuu H Sperinde J Leinonen M et al. Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol 2011 22 9 2007–2013
24. Goldhirsch A Gelber RD Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Two years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controller trial. Lancet 2013 382 9897 1021–1028
25. Pivot X Romieu G Debled M et al; PHARE trial investigators. Six months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomized phase 3 trial. Lancet Oncol 2013 14 8 741–748
26. Jones AL Barlow M Barrett-Lee PJ et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009 100 5 684–692
27. Ezaz G Long JB Gross CP Chen J Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 2014 3 1 e000472
28. Cardinale D Colombo A Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010 28 25 3910–3916
29. Guarneri V Lenihan DJ Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006 24 25 4107–4115
30. Swedberg K Cleland J Cowie MR et al. Successful treatment of heart failure with devices requires collaboration. Eur J Heart Fail 2008 10 12 1229–1235
31. Seidman A Hudis C Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002 20 5 1215–1221
32. Ewer MS Ewer SM Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010 7 10 564–575
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: July 30, 2015
Issue published: January-February 2016
Keywords
PubMed: 26350178
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 115
*Article usage tracking started in December 2016
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 5 view articles Opens in new tab
Crossref: 4
- Anticancer therapeutic agents
- Treatment‐related adverse events of antibody‐drug conjugates in clinic...
- Aptamer-Conjugated Gold Nanoparticles Targeting Human Epidermal Growth...
- Skeletal Muscle Deconditioning in Breast Cancer Patients Undergoing Ch...
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
AIOM members can access this journal content using society membership credentials.
AIOM members can access this journal content using society membership credentials.
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
